• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 123

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

Psychedelic Funding Update: Q2 2025

Daniel Pinchbeck – From Cultural Catalyst to Capitalist Co-option: Reflections on Psychedelic Science, AI, and Idealist Monism

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

Braxia Scientific Announces Voting Results from the Annual General and Special...

PT369 – Chronic Pain and Phantom Limb Pain: Could Psilocybin Be...

Numinus Re-Launches “Psychedelic Therapy Frontiers” Podcast with additional hosts and topics

Reunion Neuroscience to Present at Upcoming November Conferences

Numinus to Participate in Wonderland: Miami on November 3-5, 2022

Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With...

Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch...

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

PT368 – Ketamine, Group Work, and the Power of Just Being...

COMPASS Pathways plc to announce third quarter 2022 financial results on...

1...122123124...292Page 123 of 292

EDITOR PICKS

Erica Rex: Scientific Integrity, Psychedelic Research, and the Religious Leader Study

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD;...

Psychedelic Funding Update: Q2 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©